Metabolism – A cornerstone of cancer initiation, progression, immune evasion and treatment response

Current Opinion in Systems Biology

Volumn 8, Issue , 2018, Pages 67-72

  Lunt, Sophia Y ^a,b   Fendt, Sarah Maria ^c,d  

^a Michigan State University   (United States)

^b Michigan State University   (United States)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d Katholieke Universiteit   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL SURVIVAL; CIRCULATING TUMOR CELL; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; ENERGY METABOLISM; EPIGENETICS; GENE MUTATION; HUMAN; IMMUNE EVASION; METASTASIS; MICROFLORA; NONHUMAN; NUCLEOTIDE METABOLISM; PANCREAS CANCER; PHENOTYPE; REVIEW; TREATMENT RESPONSE; UPREGULATION;

EID: 85049152541     PISSN: None     EISSN: 24523100     Source Type: Journal    
DOI: 10.1016/j.coisb.2017.12.006     Document Type: Review

References (72)

1. Hanahan, D., Weinberg, Robert A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
2. Fendt, S.-M., Is there a therapeutic window for metabolism-based cancer therapies?. Front Endocrinol, 8, 2017, 150.
3. Lorendeau, D., Christen, S., Rinaldi, G., Fendt, S.-M., Metabolic control of signaling pathways and metabolic auto-regulation. Biol Cell 107:8 (2015), 251–272.
4. Rinaldi, G., Rossi, M., Fendt, S.-M., Metabolic interactions in cancer: cellular metabolism at the interface between the microenvironment, the cancer cell phenotype and the epigenetic landscape. WIREs Syst Biol Med, 10(1), 2018 Jan, e1397, 10.1002/wsbm.1397.
5. Frezza, C., Gottlieb, E., Mitochondria in cancer: not just innocent bystanders. Semin Canc Biol 19:1 (2009), 4–11.
6. Linehan, W.M., Srinivasan, R., Schmidt, L.S., The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7:5 (2010), 277–285.
7. Cohen, A., Holmen, S., Colman, H., IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep, 13(5), 2013 345–345.
8. Lu, C., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:7390 (2012), 474–478.
9. Xiao, M., et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Gene Dev 26:12 (2012), 1326–1338.
10. Letouze, E., et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Canc Cell 23 (2013), 739–752.
11. Laukka, T., et al. Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes. J Biol Chem 291:8 (2016), 4256–4265.
12. Sciacovelli, M., et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature 537:7621 (2016), 544–547.
13. Evenepoel, L., et al. Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genet Med 17:8 (2015), 610–620.
14. de Moura, M.B., dos Santos, L.S., Van Houten, B., Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 51:5 (2010), 391–405.
15. Lorendeau, D., et al. Dual loss of succinate dehydrogenase (SDH) and complex I activity is necessary to recapitulate the metabolic phenotype of SDH mutant tumors. Metab Eng 43:Pt B (2017 Sep), 187–197, 10.1016/j.ymben.2016.11.005.
16. Tyrakis, P.A., et al. Fumarate hydratase loss causes combined respiratory chain defects. Cell Rep 21:4 (2017), 1036–1047.
17. Elia, I., Schmieder, R., Christen, S., Fendt, S.-M., Organ-specific cancer metabolism and its potential for therapy. Handb Exp Pharmacol 233 (2016), 321–353.
18. Lunt, S.Y., Vander Heiden, M.G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27 (2011), 441–464.
19. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell, 2011, 144.
20. Luengo, A., Gui, D.Y., Vander Heiden, M.G., Targeting metabolism for cancer therapy. Cell Chem Biol 24:9 (2017), 1161–1180.
21. Vander Heiden, M.G., Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10:9 (2011), 671–684.
22. Lunt, S., et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol Cell 57:1 (2015), 95–107 This study suggests that PKM1 expression impairs nucleotide biosynthesis and consequently cellular proliferation in proliferating cells.
23. Cox, A.G., et al. Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol, 18, 2016, 886 This study establishes a link between signaling de-regulation and nucelotide biosynthesis suppporting cancer proliferation.
24. Maddocks Oliver, D.K., Labuschagne Christiaan, F., Adams Peter, D., Vousden Karen, H., Serine metabolism supports the methionine cycle and DNA/RNA methylation through de novo ATP synthesis in cancer cells. Mol Cell 61:2 (2016), 210–221.
25. Labuschagne Christiaan, F., van den Broek Niels, J.F., Mackay Gillian, M., Vousden Karen, H., Maddocks Oliver, D.K., Serine, but not Glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep 7:4 (2014), 1248–1258.
26. Keibler, M.A., et al. Metabolic requirements for cancer cell proliferation. Canc Metabol, 4(1), 2016, 16 This study comprehensivley dissects the metabolic requirments of cancer cell proliferation.
27. Gatto, F., Nookaew, I., Nielsen, J., Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc Natl Acad Sci USA 111 (2014), E866–E875.
28. Davidson Shawn, M., et al. Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metabol 23:3 (2016), 517–528 This study suggests that the the change from an in vitro to an in vivo environment alters cancer cell metabolism.
29. Christen, S., et al. Breast cancer-derived lung metastasis show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep 17:3 (2016), 837–848 This study suggests that different in vivo environments are sufficient to change the metabolism of the same cancer cells.
30. Elia, I., Fendt, S.-M., In vivo cancer metabolism is defined by the nutrient microenvironment. Transl Cancer Res 5 (2016), S1284–S1287.
31. Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA A Cancer J Clin 64:1 (2014), 9–29.
32. Massagué J., Obenauf, A.C., Metastatic colonization by circulating tumour cells. Nature, 529, 2016, 298.
33. Anderson, M., Marayati, R., Moffitt, R., Yeh, J.J., Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget 8 (2016), 56081–56094.
34. Nokin, M.-J., et al. Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. eLife, 5, 2016, e19375.
35. Payen, V.L., et al. Monocarboxylate transporter MCT1 promotes tumor metastasis independently of its activity as a lactate transporter. Canc Res, 77(20), 2017, 5591.
36. Torrano, V., et al. The metabolic co-regulator PGC1[alpha] suppresses prostate cancer metastasis. Nat Cell Biol 18:6 (2016), 645–656.
37. LeBleu, V.S., et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 16:10 (2014), 992–1003.
38. Camarda, R., et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med, 22, 2016, 427.
39. Li, J., et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell stem cell 20:3 (2017), 303–314.e305.
40. Shi, X., et al. The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Aff, 3(11), 2017 This study links post-transcriptional modifications to melanoma invasiveness.
41. Piskounova, E., et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature, 12, 2015 (527(7577)):186–191 This study suggests antioxidant metabolism as a vulnerability of circulating tumor cells.
42. Le Gal, K., et al. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med, 7(308), 2015 308re308 This study provides translational relevance to the finding that antioxidant metabolism promotes metastasis formation.
43. Schafer, Z.T., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461 (2009), 109–113.
44. Jiang, L., et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532:7598 (2016), 255–258.
45. Elia, I., et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun, 8, 2017, 15267 This study suggests energy production from proline catabolism as a requirment for lung metastatis formation.
46. Andrzejewski, S., et al. PGC-1α promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. Cell Metabol, 2017 S1550-4131(1517) 30557–30550.
47. Loo Jia, M., et al. Extracellular metabolic energetics can promote cancer progression. Cell 160:3 (2015), 393–406 This study suggests that cancer cells metastasizing to the liver scavenge extracellular metabolic energetics.
48. Dupuy, F., et al. PDK1-Dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metabol 22:4 (2015), 577–589.
49. Geeraerts, X., Bolli, E., Fendt, S.-M., Van Ginderachter, J.A., Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity. Front Immunol, 8, 2017, 289.
50. Buck, M.D., Sowell, R.T., Kaech, S.M., Pearce, E.L., Metabolic instruction of immunity. Cell 169:4 (2017), 570–586.
51. Ho, P.-C., Kaech, S.M., Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Curr Opin Immunol 46 (2017), 38–44.
52. Brand, A., et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metabol 24:5 (2016), 657–671.
53. Ma, C., et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531:7593 (2016), 253–257.
54. Angelin, A., et al. Foxp3 reprograms t cell metabolism to function in low-glucose, high-lactate environments. Cell Metabol 25:6 (2017), 1282–1293 e1287.
55. Colegio, O.R., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513:7519 (2014), 559–563.
56. Chang, C.-H., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:6 (2015), 1229–1241 This paper suggests metabolic competition as an important driver of cancer cells to evade the immune response.
57. Ho, P.-C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor t cell responses. Cell 162:6 (2015), 1217–1228 This paper provides a mechanistic link between glycolysis and an anti-tumor immune response.
58. Adams, J.L., Smothers, J., Srinivasan, R., Hoos, A., Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 14:9 (2015), 603–622.
59. Geiger, R., et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167:3 (2016), 829–842.
60. Fallarino, F., et al. T cell apoptosis by kynurenines. Developments in tryptophan and serotonin metabolism. Adv Exp Med Biol 527 (2003), 183–190.
61. Bingisser, R.M., Tilbrook, P.A., Holt, P.G., Kees, U.R., Macrophage-Derived nitric oxide regulates t cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160:12 (1998), 5729–5734.
62. Ninomiya, S., et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood, 125(25), 2015, 3905.
63. Jin, X., et al. Fructose-1,6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1-MAPK interaction. Canc Res, 2017.
64. Shukla, S.K., et al. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Canc Cell 32:1 (2017), 71–87.e77.
65. Biancur, D.E., et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism, vol. 8, 2017, 15965.
66. Tarrado-Castellarnau, M., et al. De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition. Mol Syst Biol, 13(10), 2017.
67. Le Grand, M., et al. Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression. Sci Rep, 7, 2017, 45136.
68. Farge, T., et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Canc Discov 7:7 (2017), 716–735 This paper links chemotherapy resistance to metabolic rewiring.
69. Lee, K-m, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metabol 26:4 (2017), 633–647.e637.
70. Scott, T.A., et al. Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell 169:3 (2017), 442–456.
71. García-González, A.P., et al. Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics. Cell 169:3 (2017), 431–441.
72. Gopalakrishnan, V., et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 2017 This paper suggests the microbiota as an important determinant of the immunotherapy response.